Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review)
- Authors:
- Zuzana Solárová
- Ján Mojžiš
- Peter Solár
-
Affiliations: Department of Pharmacology, Faculty of Medicine, P.J. Šafárik University, 040 01 Košice, Slovak Republic, Laboratory of Cell Biology, Institute of Biology and Ecology, Faculty of Science, P.J. Šafárik University, 040 01 Košice, Slovak Republic - Published online on: December 10, 2014 https://doi.org/10.3892/ijo.2014.2791
- Pages: 907-926
This article is mentioned in:
Abstract
|
Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 8:S55–S61. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Antimyeloma activity of heat shock protein-90 inhibition. Blood. 107:1092–1100. 2006. View Article : Google Scholar | |
|
Chiosis G, Caldas Lopes E and Solit D: Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today’s agents. Curr Opin Investig Drugs. 7:534–541. 2006.PubMed/NCBI | |
|
Teng SC, Chen YY, Su YN, et al: Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J Biol Chem. 279:14649–14655. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M and Frydman J: Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell. 131:121–135. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Okamoto J, Mikami I, Tominaga Y, et al: Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol. 3:1089–1095. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 10:537–549. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Banerji U: Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 15:9–14. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zhang T, Schwartz SJ and Sun D: New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat. 12:17–27. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kamal A, Thao L, Sensintaffar J, et al: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Isaacs JS, Xu W and Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 3:213–217. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Holzbeierlein JM, Windsperger A and Vielhauer G: Hsp90: a drug target? Curr Oncol Rep. 12:95–101. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Amolins MW and Blagg BS: Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Rev Med Chem. 9:140–152. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Krishna P and Gloor G: The Hsp90 family of proteins in Arabidopsis thaliana. Cell Stress Chaperones. 6:238–246. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hainzl O, Lapina MC, Buchner J and Richter K: The charged linker region is an important regulator of Hsp90 function. J Biol Chem. 284:22559–22567. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hawle P, Siepmann M, Harst A, Siderius M, Reusch HP and Obermann WM: The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol Cell Biol. 26:8385–8395. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CC, Lin TW, Ko TP and Wang AH: The hexameric structures of human heat shock protein 90. PLoS One. 6:e199612011. View Article : Google Scholar : PubMed/NCBI | |
|
Prodromou C, Roe SM, O’Brien R, Ladbury JE, Piper PW and Pearl LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 90:65–75. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 91:8324–8328. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Karkoulis PK, Stravopodis DJ, Margaritis LH and Voutsinas GE: 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer. 10:4812010. View Article : Google Scholar : PubMed/NCBI | |
|
Babchia N, Calipel A, Mouriaux F, Faussat AM and Mascarelli F: 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Invest Ophthalmol Vis Sci. 49:2348–2356. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Villa R, Folini M, Porta CD, et al: Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis. 24:851–859. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cervantes-Gomez F, Nimmanapalli R and Gandhi V: Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin D. Cancer Res. 69:3947–3954. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Messaoudi S, Peyrat JF, Brion JD and Alami M: Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin Ther Pat. 21:1501–1542. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Menzella HG, Tran TT, Carney JR, et al: Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus. J Med Chem. 52:1518–1521. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Turbyville TJ, Wijeratne EM, Liu MX, et al: Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J Nat Prod. 69:178–184. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pearl LH, Prodromou C and Workman P: The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J. 410:439–453. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Soga S, Shiotsu Y, Akinaga S and Sharma SV: Development of radicicol analogues. Curr Cancer Drug Targets. 3:359–369. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chiosis G, Timaul MN, Lucas B, et al: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol. 8:289–299. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kasibhatla SR, Hong K, Biamonte MA, et al: Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem. 50:2767–2778. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lundgren K, Zhang H, Brekken J, et al: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 8:921–929. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Taldone T and Chiosis G: Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem. 9:1436–1446. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chandarlapaty S, Sawai A, Ye Q, et al: SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 14:240–248. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jhaveri K, Taldone T, Modi S and Chiosis G: Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755. 2012. View Article : Google Scholar : | |
|
Jhaveri K, Ochiana SO, Dunphy MP, et al: Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs. 23:611–628. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Raad II, Hachem RY, Abi-Said D, et al: A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. Cancer. 82:403–411. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Rappa G, Shyam K, Lorico A, Fodstad O and Sartorelli AC: Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16). Oncol Res. 12:113–119. 2000. View Article : Google Scholar | |
|
Gormley NA, Orphanides G, Meyer A, Cullis PM and Maxwell A: The interaction of coumarin antibiotics with fragments of DNA gyrase B protein. Biochemistry. 35:5083–5092. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Marcu MG, Schulte TW and Neckers L: Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst. 92:242–248. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Peyrat JF, Messaoudi S, Brion JD and Alami M: Inhibitors of the heat shock protein 90: from cancer clinical trials to neurodegenerative diseases. Atlas Genet Cytogenet Oncol Haematol. 15:89–105. 2011. | |
|
Le Bras G, Radanyi C, Peyrat JF, et al: New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J Med Chem. 50:6189–6200. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Donnelly AC, Mays JR, Burlison JA, et al: The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem. 73:8901–8920. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Radanyi C, Le Bras G, Marsaud V, et al: Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett. 274:88–94. 2009. View Article : Google Scholar | |
|
Burlison JA and Blagg BS: Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Org Lett. 8:4855–4858. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shelton SN, Shawgo ME, Matthews SB, et al: KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol. 76:1314–1322. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Samadi AK, Zhang X, Mukerji R, Donnelly AC, Blagg BS and Cohen MS: A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Lett. 312:158–167. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Eskew JD, Sadikot T, Morales P, et al: Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer. 11:4682011. View Article : Google Scholar : PubMed/NCBI | |
|
Matthews SB, Vielhauer GA, Manthe CA, et al: Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate. 70:27–36. 2010. View Article : Google Scholar | |
|
Zhao H, Moroni E, Colombo G and Blagg BS: Identification of a new scaffold for hsp90 C-terminal inhibition. ACS Med Chem Lett. 5:84–88. 2013. View Article : Google Scholar | |
|
Fujiki H, Suganuma M, Okabe S, et al: Mechanistic findings of green tea as cancer preventive for humans. Proc Soc Exp Biol Med. 220:225–228. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Palermo CM, Westlake CA and Gasiewicz TA: Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry. 44:5041–5052. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zhang T, Jiang Y, Lee HF, Schwartz SJ and Sun D: (−)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol Pharm. 6:1152–1159. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yin Z, Henry EC and Gasiewicz TA: (−)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry. 48:336–345. 2009. View Article : Google Scholar : | |
|
Tran PL, Kim SA, Choi HS, Yoon JH and Ahn SG: Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer. 10:2762010. View Article : Google Scholar : PubMed/NCBI | |
|
Jacquemont C, Simon JA, D’Andrea AD and Taniguchi T: Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer. 11:262012. View Article : Google Scholar : PubMed/NCBI | |
|
Peron M, Bonvini P and Rosolen A: Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro. BMC Cancer. 12:2332012. View Article : Google Scholar : PubMed/NCBI | |
|
Kabakov AE, Kudryavtsev VA and Gabai VL: Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med (Berl). 88:241–247. 2010. View Article : Google Scholar | |
|
Vaseva AV, Yallowitz AR, Marchenko ND, Xu S and Moll UM: Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis. 2:e1562011. View Article : Google Scholar : PubMed/NCBI | |
|
Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T and Hamakawa H: P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines. Int J Oncol. 29:1111–1117. 2006.PubMed/NCBI | |
|
To KK, Yu L, Liu S, Fu J and Cho CH: Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol Carcinog. 51:449–464. 2012. View Article : Google Scholar | |
|
Wu X, Wanders A, Wardega P, et al: Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer. 100:334–343. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Floris G, Debiec-Rychter M, Wozniak A, et al: The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther. 10:1897–1908. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Floris G, Sciot R, Wozniak A, et al: The novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res. 17:5604–5614. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth T, Van Looy T, Curry JE, et al: The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther. 11:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lang SA, Moser C, Fichnter-Feigl S, et al: Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology. 49:523–532. 2009. View Article : Google Scholar | |
|
Gloesenkamp C, Nitzsche B, Lim AR, et al: Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol. 40:1659–1667. 2012.PubMed/NCBI | |
|
Oikonomou E, Koc M, Sourkova V, Andera L and Pintzas A: Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One. 6:e216322011. View Article : Google Scholar : PubMed/NCBI | |
|
Moser C, Lang SA, Kainz S, et al: Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther. 6:2868–2878. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rakitina TV, Vasilevskaya IA and O’Dwyer PJ: Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. Biochem Pharmacol. 73:1715–1726. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Vasilevskaya IA, Rakitina TV and O’Dwyer PJ: Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol. 65:235–243. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
McNamara AV, Barclay M, Watson AJ and Jenkins JR: Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins. Biochem Pharmacol. 83:355–367. 2012. View Article : Google Scholar | |
|
Tse AN, Sheikh TN, Alan H, Chou TC and Schwartz GK: 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol. 75:124–133. 2009. View Article : Google Scholar : | |
|
Moran DM, Gawlak G, Jayaprakash MS, Mayar S and Maki CG: Geldanamycin promotes premature mitotic entry and micro-nucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 27:5567–5577. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Giessrigl B, Krieger S, Rosner M, et al: Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells. Hum Mol Genet. 21:4615–4627. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Huston A, Leleu X, Jia X, et al: Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 14:865–874. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dote H, Cerna D, Burgan WE, Camphausen K and Tofilon PJ: ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res. 65:6967–6975. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zhang T, Schwartz SJ and Sun D: Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. Nutr Cancer. 63:1151–1159. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
De Raedt T, Walton Z, Yecies JL, et al: Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 20:400–413. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Acquaviva J, Smith DL, Sang J, et al: Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther. 11:2633–2643. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Proia DA, Sang J, He S, et al: Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 30:2201–2209. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bao R, Lai CJ, Wang DG, et al: Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 8:3296–3306. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bao R, Lai CJ, Qu H, et al: CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 15:4046–4057. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Koizumi H, Yamada T, Takeuchi S, et al: Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 7:1078–1085. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu L, Kikuchi E, Xu C, et al: Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res. 72:3302–3311. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rice JW, Veal JM, Barabasz A, et al: Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib. Oncol Res. 18:229–242. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai MS, Weng SH, Chen HJ, et al: Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide. Mol Cancer Ther. 11:561–571. 2012. View Article : Google Scholar | |
|
Weng SH, Tseng SC, Huang YC, Chen HJ and Lin YW: Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells. Biochem Pharmacol. 84:126–136. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Katayama R, Khan TM, Benes C, et al: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA. 108:7535–7540. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Normant E, Paez G, West KA, et al: The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 30:2581–2586. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Solit DB, Osman I, Polsky D, et al: Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res. 14:8302–8307. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Heuckmann JM, Balke-Want H, Malchers F, et al: Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 18:4682–4690. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sang J, Acquaviva J, Friedland JC, et al: Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 3:430–443. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Koll TT, Feis SS, Wright MH, et al: HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther. 7:1985–1992. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Segawa T, Fujii Y, Tanaka A, et al: Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med. 33:559–564. 2014. | |
|
Kim YM and Pyo H: Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines. DNA Cell Biol. 31:15–29. 2012. View Article : Google Scholar : | |
|
Sudo M, Chin TM, Mori S, et al: Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol. 71:1325–1334. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wainberg ZA, Anghel A, Rogers AM, et al: Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 12:509–519. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ono N, Yamazaki T, Nakanishi Y, et al: Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci. 103:342–349. 2012. View Article : Google Scholar | |
|
Scaltriti M, Serra V, Normant E, et al: Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther. 10:817–824. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chandarlapaty S, Scaltriti M, Angelini P, et al: Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 29:325–334. 2010. View Article : Google Scholar | |
|
Meng Q, Chen X, Sun L, Zhao C, Sui G and Cai L: Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90. Mol Cell Biochem. 348:165–171. 2011. View Article : Google Scholar | |
|
Solit DB, Basso AD, Olshen AB, Scher HI and Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 63:2139–2144. 2003.PubMed/NCBI | |
|
Wong C and Chen S: Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Res. 69:8670–8677. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wong C, Wang X, Smith D, Reddy K and Chen S: AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Res Treat. 134:671–681. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pashtan I, Tsutsumi S, Wang S, Xu W and Neckers L: Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell Cycle. 7:2936–2941. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Palacios C, Lopez-Perez AI and Lopez-Rivas A: Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells. Cancer Lett. 287:207–215. 2010. View Article : Google Scholar | |
|
Stecklein SR, Kumaraswamy E, Behbod F, et al: BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci USA. 109:13650–13655. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Benezra R, Henke E, Ciarrocchi A, et al: Induction of complete regressions of oncogene-induced breast tumors in mice. Cold Spring Harb Symp Quant Biol. 70:375–381. 2005. View Article : Google Scholar | |
|
Smith V, Hobbs S, Court W, Eccles S, Workman P and Kelland LR: ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res. 22:1993–1999. 2002.PubMed/NCBI | |
|
Solar P, Horvath V, Kleban J, et al: Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma. 54:127–130. 2007.PubMed/NCBI | |
|
Sain N, Krishnan B, Ormerod MG, et al: Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther. 5:1197–1208. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mollapour M, Tsutsumi S, Donnelly AC, et al: Swe1 Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell. 37:333–343. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Iwai A, Bourboulia D, Mollapour M, et al: Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle. 11:3649–3655. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lamoureux F, Thomas C, Yin MJ, et al: Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 71:5838–5849. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
O’Malley KJ, Langmann G, Ai J, Ramos-Garcia R, Vessella RL and Wang Z: Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate. 72:1117–1123. 2012. View Article : Google Scholar | |
|
Huang HC, Yang Y, Nanda A, Koria P and Rege K: Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices. Nanomedicine (Lond). 6:459–473. 2011. View Article : Google Scholar | |
|
Lamottke B, Kaiser M, Mieth M, et al: The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol. 88:406–415. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Stuhmer T, Iskandarov K, Gao Z, et al: Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells. Anticancer Res. 32:453–462. 2012.PubMed/NCBI | |
|
Chatterjee M, Andrulis M, Stuhmer T, et al: The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica. 98:1132–1141. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kaiser M, Lamottke B, Mieth M, et al: Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol. 84:337–344. 2010. View Article : Google Scholar | |
|
Yasui H, Hideshima T, Ikeda H, et al: BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol. 136:414–423. 2007. View Article : Google Scholar | |
|
Weigert O, Lane AA, Bird L, et al: Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 209:259–273. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fiskus W, Verstovsek S, Manshouri T, et al: Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 17:7347–7358. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fiskus W, Rao R, Fernandez P, et al: Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood. 112:2896–2905. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kaufmann SH, Karp JE, Litzow MR, et al: Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 96:1619–1626. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Best OG, Che Y, Singh N, Forsyth C, Christopherson RI and Mulligan SP: The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leuk Lymphoma. 53:1367–1375. 2012. View Article : Google Scholar | |
|
Jones DT, Addison E, North JM, et al: Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells’ sensitivity to cytotoxic drugs. Blood. 103:1855–1861. 2004. View Article : Google Scholar | |
|
Walsby E, Pearce L, Burnett AK, Fegan C and Pepper C: The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget. 3:525–534. 2012.PubMed/NCBI | |
|
Johnson AJ, Wagner AJ, Cheney CM, et al: Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol. 139:837–844. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Blagosklonny MV, Fojo T, Bhalla KN, et al: The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 15:1537–1543. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Peng C, Brain J, Hu Y, et al: Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood. 110:678–685. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tauchi T, Okabe S, Ashihara E, Kimura S, Maekawa T and Ohyashiki K: Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene. 30:2789–2797. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA and Blagosklonny MV: Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther. 4:484–490. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Roue G, Perez-Galan P, Mozos A, et al: The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosur-vival ER chaperone BiP/Grp78. Blood. 117:1270–1279. 2011. View Article : Google Scholar | |
|
Dungey FA, Caldecott KW and Chalmers AJ: Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther. 8:2243–2254. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ohba S, Hirose Y, Yoshida K, Yazaki T and Kawase T: Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. J Neurosurg. 112:33–42. 2010. View Article : Google Scholar | |
|
Siegelin MD, Habel A and Gaiser T: 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol Dis. 33:243–249. 2009. View Article : Google Scholar | |
|
Sauvageot CM, Weatherbee JL, Kesari S, et al: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 11:109–121. 2009. View Article : Google Scholar : | |
|
Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 18:2502–2514. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ito A, Saito H, Mitobe K, et al: Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature. Cancer Sci. 100:558–564. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Acquaviva J, Smith DL, Jimenez JP, et al: Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther. 13:353–363. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tatokoro M, Koga F, Yoshida S, et al: Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 131:987–996. 2012. View Article : Google Scholar | |
|
Yoshida S, Koga F, Tatokoro M, et al: Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 10:4291–4299. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sato A and Asano T, Ito K and Asano T: 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1. Int J Oncol. 41:46–52. 2012.PubMed/NCBI | |
|
Ma L, Sato F, Sato R, et al: Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer. Oncol Rep. 31:2482–2492. 2014.PubMed/NCBI | |
|
Yin X, Zhang H, Lundgren K, Wilson L, Burrows F and Shores CG: BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 126:1216–1225. 2010. | |
|
Misso G, Giuberti G, Lombardi A, et al: Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. J Cell Physiol. 228:130–141. 2013. View Article : Google Scholar | |
|
Lee CH, Hong HM, Chang YY and Chang WW: Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie. 94:1382–1389. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Newman B, Liu Y, Lee HF, Sun D and Wang Y: HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res. 72:4551–4561. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P: DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 91:1940–1949. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Gaspar N, Sharp SY, Pacey S, et al: Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 69:1966–1975. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Neely L, Lundgren K, et al: BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer. 126:1226–1234. 2010. | |
|
Sharp SY, Boxall K, Rowlands M, et al: In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 67:2206–2216. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sharp SY, Prodromou C, Boxall K, et al: Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther. 6:1198–1211. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gaspar N, Sharp SY, Eccles SA, et al: Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther. 9:1219–1233. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
McCollum AK, Teneyck CJ, Sauer BM, Toft DO and Erlichman C: Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 66:10967–10975. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sharp SY, Roe SM, Kazlauskas E, et al: Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. PLoS One. 7:e446422012. View Article : Google Scholar : PubMed/NCBI | |
|
McConnell JR and McAlpine SR: Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett. 23:1923–1928. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A and Gleave ME: Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur Urol. 66:145–155. 2013. View Article : Google Scholar | |
|
Guo F, Rocha K, Bali P, et al: Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 65:10536–10544. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Pimienta G, Herbert KM and Regan L: A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines. Mol Pharm. 8:2252–2261. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Miyagawa T, Saito H, Minamiya Y, et al: Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature. Int J Clin Oncol. 19:722–730. 2014. View Article : Google Scholar | |
|
Ronnen EA, Kondagunta GV, Ishill N, et al: A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs. 24:543–546. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Heath EI, Hillman DW, Vaishampayan U, et al: A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 14:7940–7946. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV, Gettinger S, Senzer NN, et al: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 28:4953–4960. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Oh WK, Galsky MD, Stadler WM, et al: Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 78:626–630. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Richardson PG, Chanan-Khan AA, Lonial S, et al: Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 153:729–740. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Modi S, Stopeck A, Linden H, et al: HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gartner EM, Silverman P, Simon M, et al: A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 131:933–937. 2012. View Article : Google Scholar | |
|
Pacey S, Gore M, Chao D, et al: A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 30:341–349. 2012. View Article : Google Scholar | |
|
Socinski MA, Goldman J, El-Hariry I, et al: A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 19:3068–3077. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Modi S, Saura C, Henderson C, et al: A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res Treat. 139:107–113. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jhaveri K, Chandarlapaty S, Lake D, et al: A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 14:154–160. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ui T, Morishima K, Saito S, et al: The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Oncol Rep. 31:619–624. 2014. | |
|
Akimoto T, Nonaka T, Harashima K, Sakurai H, Ishikawa H and Mitsuhashi N: Radicicol potentiates heat-induced cell killing in a human oesophageal cancer cell line: the Hsp90 chaperone complex as a new molecular target for enhancement of thermosensitivity. Int J Radiat Biol. 80:483–492. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Burkitt M, Magee C, O’Connor D, Campbell F, Cornford P and Greenhalf W: Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. Mol Carcinog. 46:466–475. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cao X, Bloomston M, Zhang T, et al: Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res. 14:1831–1839. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cao X, Jia G, Zhang T, et al: Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol. 62:985–994. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang T, Li Y, Zhu Z, Gu M, Newman B and Sun D: MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. Mol Pharm. 7:1576–1584. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Milanovic D, Firat E, Grosu AL and Niedermann G: Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990. Radiat Oncol. 8:422013. View Article : Google Scholar : PubMed/NCBI | |
|
Machida H, Matsumoto Y, Shirai M and Kubota N: Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol. 79:973–980. 2003. View Article : Google Scholar | |
|
Vasilevskaya IA and O’Dwyer PJ: 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol. 70:580–589. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Holmes JL, Sharp SY, Hobbs S and Workman P: Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 68:1188–1197. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Saturno G, Valenti M, De Haven Brandon A, et al: Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget. 4:1185–1198. 2013.PubMed/NCBI | |
|
He S, Smith DL, Sequeira M, Sang J, Bates RC and Proia DA: The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs. 32:577–586. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen DM, Chen A, Mixon A and Schrump DS: Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. J Thorac Cardiovasc Surg. 118:908–915. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Wen W, Liu W, Shao Y and Chen L: VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines. Exp Biol Med (Maywood). 239:638–645. 2014. View Article : Google Scholar | |
|
Zismanov V, Drucker L and Gottfried M: ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors. Pulm Pharmacol Ther. 26:388–394. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zismanov V, Drucker L and Gottfried M: Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration. Anticancer Drugs. 25:998–1006. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Akbay E, Mikse O, et al: Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res. 20:1204–1211. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Miyajima N, Tsutsumi S, Sourbier C, et al: The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res. 73:7022–7033. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Smith DL, Acquaviva J, Sequeira M, et al: The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol. Aug 1–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Ono N, Yamazaki T, Tsukaguchi T, et al: Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci. 104:1346–1352. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jang WJ, Jung SK, Kang JS, et al: Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant NSCLCs with Met amplification. Cancer Sci. Aug 13–2014.(Epub ahead of print). View Article : Google Scholar | |
|
Ma Y, Lakshmikanthan V, Lewis RW and Kumar MV: Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol Cancer Ther. 5:170–178. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Senju M, Sueoka N, Sato A, et al: Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol. 132:150–158. 2006. View Article : Google Scholar | |
|
Russell JS, Burgan W, Oswald KA, Camphausen K and Tofilon PJ: Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res. 9:3749–3755. 2003.PubMed/NCBI | |
|
Bisht KS, Bradbury CM, Mattson D, et al: Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 63:8984–8995. 2003.PubMed/NCBI | |
|
Sawai A, Chandarlapaty S, Greulich H, et al: Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res. 68:589–596. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bai L, Xu S, Chen W, et al: Blocking NF-kappaB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death. Apoptosis. 16:45–54. 2011. View Article : Google Scholar : | |
|
Mimnaugh EG, Xu W, Vos M, et al: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. 3:551–566. 2004.PubMed/NCBI | |
|
Raja SM, Clubb RJ, Bhattacharyya M, et al: A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther. 7:1630–1640. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J and Vereb G: Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett. 104:146–155. 2006. View Article : Google Scholar | |
|
Roforth MM and Tan C: Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells. Anticancer Drugs. 19:681–688. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Munster PN, Basso A, Solit D, Norton L and Rosen N: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E A Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res. 7:2155–2158. 2001. | |
|
Ferrario A, Rucker N, Wong S, Luna M and Gomer CJ: Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res. 67:4989–4995. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hasenstein JR, Shin HC, Kasmerchak K, Buehler D, Kwon GS and Kozak KR: Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther. 11:2233–2242. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Solar P, Ferenc P, Koval J, et al: Photoactivated hypericin induces downregulation of HER2 gene expression. Radiat Res. 175:51–56. 2011. View Article : Google Scholar | |
|
Chen SM, Guo CL, Shi JJ, et al: HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer. Int J Cancer. 135:2462–2474. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Banerji U, Sain N, Sharp SY, et al: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 62:769–778. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gray PJ Jr, Stevenson MA and Calderwood SK: Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 67:11942–11950. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Paduano F, Villa R, Pennati M, et al: Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther. 5:179–186. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Gandhi N, Wild AT, Chettiar ST, et al: Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther. 14:347–356. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L and Pili R: Inhibition of hsp90 augments docetaxel therapy in castrate resistant prostate cancer. PLoS One. 9:e1036802014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, Ma J, Zhu HY, et al: Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 10:1042011. View Article : Google Scholar : PubMed/NCBI | |
|
Shammas MA, Koley H, Bertheau RC, et al: Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 22:1410–1418. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Duus J, Bahar HI, Venkataraman G, et al: Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma. 47:1369–1378. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Francis LK, Alsayed Y, Leleu X, et al: Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 12:6826–6835. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cervantes-Gomez F, Nimmanapalli R and Gandhi V: ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J Pharmacol Exp Ther. 339:545–554. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sydor JR, Normant E, Pien CS, et al: Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 103:17408–17413. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Heimberger T, Andrulis M, Riedel S, et al: The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol. 160:465–476. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sugimoto K, Sasaki M, Isobe Y, et al: Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene. 27:3091–3101. 2008. View Article : Google Scholar | |
|
Haaland I, Opsahl JA, Berven FS, et al: Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 13:1162014. View Article : Google Scholar : PubMed/NCBI | |
|
Rahmani M, Yu C, Dai Y, et al: Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. 63:8420–8427. 2003.PubMed/NCBI | |
|
Jia W, Yu C, Rahmani M, et al: Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood. 102:1824–1832. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Q, Nishiuchi R, Kitamura T and Kersey JH: Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia. 19:1605–1612. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mesa RA, Loegering D, Powell HL, et al: Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood. 106:318–327. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
George P, Bali P, Annavarapu S, et al: Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 105:1768–1776. 2005. View Article : Google Scholar | |
|
George P, Bali P, Cohen P, et al: Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 64:3645–3652. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Radujkovic A, Schad M, Topaly J, et al: Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 19:1198–1206. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rao R, Fiskus W, Yang Y, et al: HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood. 112:1886–1893. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
McCaig AM, Cosimo E, Leach MT and Michie AM: Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol. 153:199–211. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Walsby EJ, Lazenby M, Pepper CJ, Knapper S and Burnett AK: The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Br J Haematol. 161:57–67. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Best OG and Mulligan SP: Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leuk Lymphoma. 53:2314–2320. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Robles AI, Wright MH, Gandhi B, et al: Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res. 12:6547–6556. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rao R, Lee P, Fiskus W, et al: Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther. 8:1273–1280. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Abramson JS, Chen W, Juszczynski P, et al: The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haematol. 144:358–366. 2009. View Article : Google Scholar | |
|
Premkumar DR, Arnold B, Jane EP and Pollack IF: Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol Carcinog. 45:47–59. 2006. View Article : Google Scholar | |
|
Premkumar DR, Arnold B and Pollack IF: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. Mol Carcinog. 45:288–301. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jane EP and Pollack IF: The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Lett. 268:46–55. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Choi EJ, Cho BJ, Lee DJ, et al: Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer. 14:172014. View Article : Google Scholar : PubMed/NCBI | |
|
Bull EE, Dote H, Brady KJ, et al: Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res. 10:8077–8084. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wachsberger PR, Lawrence YR, Liu Y, et al: Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 140:573–582. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gallerne C, Prola A and Lemaire C: Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta. 1833:1356–1366. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CC, Tu CF, Yen MC, et al: Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein. Mol Ther. 15:404–410. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Roh JL, Kim EH, Park HB and Park JY: The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer. Cell Death Dis. 4:e9562013. View Article : Google Scholar : PubMed/NCBI | |
|
Bagatell R, Beliakoff J, David CL, Marron MT and Whitesell L: Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer. 113:179–188. 2005. View Article : Google Scholar | |
|
Fu W, Sharma SS, Ma L, et al: Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis. 4:e5662013. View Article : Google Scholar : PubMed/NCBI | |
|
Mimnaugh EG, Xu W, Vos M, Yuan X and Neckers L: Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol Cancer Res. 4:667–681. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Martins AS, Ordonez JL, Garcia-Sanchez A, et al: A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 68:6260–6270. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Neznanov N, Gorbachev AV, Neznanova L, et al: Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle. 8:3960–3970. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Enomoto A, Fukasawa T, Takamatsu N, et al: The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. Eur J Cancer. 49:3547–3558. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chinn DC, Holland WS, Yoon JM, Zwerdling T and Mack PC: Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer. 58:885–890. 2012. View Article : Google Scholar |
